olanzapine / Generic mfg. - LARVOL DELTA

Potential Role of the Triple Receptor Agonist Retatrutide in Antipsychotic-Associated Metabolic Dysfunction Among Clozapine- and Olanzapine-Treated Schizophrenia Spectrum Disorders: A Narrative Review and Theoretical Framework. (PubMed, Biomedicines) - "Existing pharmacological interventions, including metformin and glucagon-like peptide-1 receptor agonists (GLP-1RAs), produce clinically meaningful but often incomplete benefits. Future studies should therefore characterize gastrointestinal tolerability, potential interaction with clozapine-associated gastrointestinal hypomotility, possible effects on clozapine and olanzapine exposure, adherence and feasibility, and the dysesthesia observed in retatrutide trials, which was dose-related in most but not all trials. Dedicated randomized controlled trials are needed to determine the efficacy and safety of retatrutide in patients with schizophrenia spectrum disorders receiving clozapine or olanzapine."

Journal • Review • Anesthesia • CNS Disorders • Genetic Disorders • Metabolic Disorders • Obesity • Psychiatry • Schizophrenia

Research trends in olanzapine in treating schizophrenia from 2010 to 2026: A bibliometric analysis based on the Web of Science Core Collection. (PubMed, Medicine (Baltimore)) - "Research on olanzapine for the treatment of schizophrenia is ongoing. Current studies have shifted from efficacy verification to safety monitoring, with growing emphasis on population-based individualized dose adjustment, metabolic risk management, and large-sample comparative clinical studies for clinical guideline optimization."

Journal • CNS Disorders • Mental Retardation • Psychiatry • Schizophrenia

Hydrogel-Based Depot Systems in Psychiatric Pharmacotherapy: A Narrative Review Rethinking Long-Acting Drug Delivery. (PubMed, Gels) - "Current research has primarily focused on antipsychotic delivery, where hydrogel formulations of risperidone, paliperidone, aripiprazole, olanzapine, quetiapine and the investigational peptide PAOPA show possible sustained drug release and prolonged therapeutic activity in preclinical models...Collectively, current evidence supports the technological potential of hydrogel-based systems to provide tunable drug loading, depot formation, and sustained release. However, their development as clinically meaningful next-generation LAI therapies will require long-term in vivo evaluation, robust pharmacokinetic-pharmacodynamic characterization, injection-site safety assessment, reproducible and scalable manufacturing, and well-designed clinical trials."

Journal • Review • CNS Disorders • Mental Retardation • Psychiatry

Real-World Analysis of Olanzapine and Functional Outcomes in Outpatient Cancer Rehabilitation. (PubMed, Cancers (Basel)) - "However, fatigue was a significant predictor of PT goal completion across the cohort (p = 0.017), highlighting the need for future studies to investigate this relationship more deeply. These results indicate that the effects of olanzapine may vary between different clinical populations and suggest that further investigation into adjuvant therapies remains critical for optimizing care for cancer patients with anorexia."

Journal • Real-world evidence • Anorexia • Cachexia • CNS Disorders • Fatigue • Oncology • Vascular Neurology

Multi criteria evaluation of schizophrenia drugs: DFT, ADMET, and molecular docking investigations. (PubMed, Comput Biol Chem) - "Global reactivity descriptors indicated a higher oxidative stability in aripiprazole, opposite to the marked reactivity sensitivity of haloperidol...Structural divergence was observed in Olanzapine and Haloperidol...Risperidone showed the highest affinity (-10.0 kcal/mol) due to strong electrostatic interactions with the primary anchoring residue Asp474 and hydrophobic stabilisation through Tyr142, Trp322 and Pro383...The MEP maps confirmed that the binding affinity to GlyT1 is the large negative potential localisation around the hydrogen-bond accepting heteroatoms, as well as the large electrochemically neutral hydrophobic regions. These insights provide a crucial integrated framework for optimising the next generation antipsychotic drug design."

Journal • CNS Disorders • Psychiatry • Schizophrenia

Psychiatric emergency multi-center randomized clinical trial on unanswered questions of pharmacotherapy in acute-phase schizophrenia (clinicaltrials.gov) - P=N/A | N=200 | Completed | Sponsor: Juntendo University Faculty of Medicine | Unknown status ➔ Completed

Trial completion • CNS Disorders • Psychiatry • Schizophrenia • Schizophreniform Disorder

Study of Palonosetron / Dexamethasone / Olanzapine for nausea and vomiting induced chemotherapy for breast cancer. (clinicaltrials.gov) - P2 | N=55 | Completed | Sponsor: Saitama Breast Cancer Clinical Study Group (SBCCSG) | Unknown status ➔ Completed

Trial completion • Breast Cancer • Oncology • Solid Tumor

Psychiatric emergency multi-center randomized clinical trial on unanswered questions of pharmacotherapy in acute-phase schizophrenia (clinicaltrials.gov) - P=N/A | N=200 | Completed | Sponsor: Juntendo University Faculty of Medicine | Unknown status ➔ Completed

Trial completion • CNS Disorders • Psychiatry • Schizophrenia • Schizophreniform Disorder

Body Weight Changes After Switching to Lurasidone for Antipsychotic-induced Weight Gain in Bipolar Disorder (clinicaltrials.gov) - P=N/A | N=155 | Completed | Sponsor: Dong-Wook Kim

New trial • Bipolar Disorder • CNS Disorders • Mood Disorders • Psychiatry

Chorea-predominant SCA5 mimicking Huntington's disease: A case report with a novel SPTBN2 variant. (PubMed, Clin Park Relat Disord) - "Initially misdiagnosed with HD, he received olanzapine, achieving partial relief...The identification of the novel c.2531G > A variant expands the phenotypic and mutational spectrum of SCA5. It underscores that WES should be considered early in autosomal dominant chorea with frontal-horn enlargement, particularly when cerebellar signs are subtle, to prevent diagnostic errors."

Journal • Ataxia • CNS Disorders • Genetic Disorders • Huntington's Disease • Movement Disorders

GLUT5-Mediated Disruption of the Gut-Testis Axis Deteriorates Olanzapine-Induced Testicular Fibrosis and is Ameliorated by Dapagliflozin. (PubMed, Drug Des Devel Ther) - "However, DAP could reverse these adverse effects via downregulating GLUT5, thus supporting its potential as a therapeutic agent for OLA-induced testicular fibrosis. The above results could provide novel mechanistic insights and identify new molecular targets for the prevention and treatment of OLA-induced male reproductive toxicity."

Journal • Fibrosis • Immunology

Fosrolapitant and Palonosetron for Highly Emetogenic ADC-Induced Nausea and Vomiting in Solid Tumors (clinicaltrials.gov) - P2 | N=60 | Active, not recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

New P2 trial • Oncology • Solid Tumor

A Phase II Clinical Trial Evaluating the Antiemetic Effect and Safety of a Five-Drug Combination Therapy for Zolbetuximab, Including Olanzapine and Antihistamines, with or without Pre-Treatment Olanzapine (ESMO 2026) - No abstract available

Clinical • Combination therapy • P2 data • Oncology

The Efficacy And Safety Of Mirtazapine Vs Olanzapine In Preventing Chemotherapy Induced Nausea And Vomiting In Combination With The Triplet Regimen In Patients Receiving Highly Emetogenic Chemotherapy- An Open Label, Prospective, Randomized Controlled Study (ESMO 2026) - No abstract available

CINV • Clinical • Combination therapy • Chemotherapy-Induced Nausea and Vomiting • Oncology

The Comparison Between Sublingual Administration of Orally Disintegrating Olanzapine versus Intravenous Administration of Metoclopramide for Treatment of Breakthrough Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Chemotherapy (ESMO 2026) - No abstract available

CINV • Clinical • Chemotherapy-Induced Nausea and Vomiting • Oncology

The Contemporary "Balloon Man" Phenotype: A Giant Fecaloma in a Patient on Chronic Antipsychotics (ACG 2026) - "Psychiatry transitioned him from clozapine and olanzapine to haloperidol without breakthrough psychosis. He was discharged on prucalopride, polyethylene glycol, bisacodyl, and lactulose...Figure: Fig 2. Prior flexible sigmoidoscopy showing 2-3 cm clean-based rectosigmoid ulcers, consistent with chronic stercoral pressure injury from recurrent fecal loading."

Clinical • Acute Kidney Injury • CNS Disorders • Constipation • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Mental Retardation • Nephrology • Renal Disease • Schizophrenia

Anti-psychotic therapeutics modify gut microbial metabolism and modulate susceptibility to gastrointestinal infection in mice. (PubMed, bioRxiv) - "Using a murine model, we evaluated haloperidol, olanzapine, risperidone, and quetiapine through longitudinal microbiome profiling, untargeted metabolomic fingerprinting, behavioral testing, and enteric infection challenge. Although microbial compositional changes did not fully account for functional outcomes, their integration with metabolomics data revealed disrupted bacterial taxa-metabolite networks and loss of homeostatic metabolic modules. These results provide a potential mechanistic link between the disruptive effects of antipsychotics on the microbiome and impaired colonization resistance."

Journal • Preclinical • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Infectious Disease

Management of intractable emergence agitation with emotional and behavioural disinhibition in a child with anxiety requiring multiple anaesthetics. (PubMed, Anaesth Rep) - "After conventional pharmacological and non-pharmacological strategies were unsuccessful, the combination of olanzapine premedication with the ongoing anaesthetic regimen resolved her emergence agitation on multiple subsequent anaesthetics. We suggest a novel approach for the management of intractable emergence agitation and highlight the need for early involvement of mental health providers in the unique context of iterative anaesthesia in children with cancer."

Journal • Anesthesia • B Acute Lymphoblastic Leukemia • CNS Disorders • Hematological Malignancies • Leukemia • Mood Disorders • Oncology • Pediatrics • Psychiatry

Clozapine-associated cardiotoxicity: Risk factors and long-term cardiovascular outcomes from a multicentre propensity-matched analysis. (PubMed, Arch Cardiovasc Dis) - "Early clozapine cardiotoxicity predicts long-term heart failure, arrhythmias and cardiomyopathy, but not mortality. Risk is higher in males, younger patients, those with obesity and those taking valproate or multiple antipsychotics. Findings support early risk stratification and ongoing cardiovascular surveillance."

Journal • Cardiomyopathy • Cardiovascular • CNS Disorders • Congestive Heart Failure • Genetic Disorders • Heart Failure • Inflammation • Obesity

Comparative efficacy of antipsychotics for reducing aggression in schizophrenia: systematic review and network meta-analysis. (PubMed, Br J Psychiatry) - "Antipsychotics reduced hostility and aggressive behaviour in predominantly short- to medium-term studies. Clozapine, paliperidone and olanzapine appeared most effective, although low-certainty evidence limits conclusions about differences between antipsychotics. Further trials with aggressive behaviour as the primary outcome and longer follow-up are needed."

Journal • Retrospective data • Review • CNS Disorders • Psychiatry • Schizophrenia

A randomized, open-label phase III trial Evaluating Low-Dose Vs standard-dose Olanzapine with triple Antiemetic therapy for Prevention of highly emetogenic chemotherapy- induced Nausea and vomiting in solid tumors (OLAnzaPiNE) (SABCS 2023) - "Methods Solid tumors planned for anthracycline-cyclophosphamide & high-dose cisplatin chemotherapy was randomized (1:1) to receive either 10mg OLZ (standard arm) or 2.5mg (experimental arm) till day 4 with TAE regimen [5-hydroxytryptamine type 3 (5-HT3) receptor antagonists, dexamethasone (SD, without delayed doses), and neurokinin-1 (NK1) receptor antagonists] in both arms. This merits wide recognition as a new steroid sparing antiemetic regimen of choice with HEC. Demographic data, Clinical characteristics and Outcomes"

Clinical • P3 data • Breast Cancer • Oncology • Solid Tumor

A multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B) (ESMO 2024) - "OLZ 5mg for 6 days with 5-HT3 RA and DEX could be an effective option for pts treated with T-DXd to reduce delayed and persistent NV."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

A randomized, double-blind, placebo-controlled phase II study of olanzapine based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B). (PubMed, Ann Oncol) - "Olanzapine 5mg for 6 days with 5-HT3RA and dexamethasone appears effective for T-DXd-treated patients to prevent delayed and persistent nausea and vomiting."

Clinical • Journal • P2 data • Anorexia • Breast Cancer • Diabetes • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Primary analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide alone as maintenance therapy post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; SEALAND) (ASH 2025) - P3 | "Introduction:Selinexor (S) is an oral selective exportin 1 inhibitor approved in relapsed multiple myeloma (MM) incombination with bortezomib (V) and dexamethasone (d)...Patients received ondansetron 8mg immediately prior to, and 8-hours following each S dose.Additional ondansetron and low-dose olanzapine were used as required for break-through nausea andvomiting...In this randomized phase III study, the addition of low-dose S to R maintenance following ASCT did notresult in a significant PFS benefit compared to R alone in NDMM. Although a higher CR rate was observedwith SR, this came at the cost of increased toxicity, including more infections, cytopenias andgastrointestinal AEs. Quality of life, as assessed by EORTC QLQ-C30 and MY20, was comparable betweenarms."

Clinical • P3 data • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Thrombocytopenia • Transplantation • XPO1

High Risk of Metabolic Side Effects Among New Paediatric Antipsychotic Users in Sweden-A Register-Based Study. (PubMed, Pharmacoepidemiol Drug Saf) - "The overall risk of metabolic side effects is considerable, with higher relative risks in girls, especially younger girls. These findings highlight the need for carefully considered treatment and attentive monitoring when initiating antipsychotics in children."

Adverse events • Journal • CNS Disorders • Genetic Disorders • Obesity • Pediatrics